Skip to content

MASLD — Bibliography

Every paper cited anywhere in conditions/masld/wiki/, grouped by the topic of the page that principally uses it. One line per paper: citation, PMID, tags, and the wiki pages that cite it. Every PMID here was retrieved from a live PubMed E-utilities query on 2026-09-02; none was written from memory.

Papers are listed once, under their primary topic; the "cited by" field shows every page that uses them.

Total: 367 verified papers (274 at build/audit; 93 added in the 2026-09-02 depth pass, marked in each section).

Nomenclature, definitions and MetALD

25 papers.

  • Angulo P et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. PMID 25935633 — tags: [fibrosis, histology] — cited by: natural-history-and-fibrosis-progression.md, nomenclature-and-definitions.md, overview.md
  • Arab JP et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82(4):744-756. PMID 39608457 — tags: [alcohol, guideline] — cited by: guidelines.md, nomenclature-and-definitions.md, red-flags-and-safety-concerns.md
  • Ayares G et al. MetALD: New Perspectives on an Old Overlooked Disease. Liver Int. 2025;45(5):e70017. PMID 40179033 — tags: [review] — cited by: nomenclature-and-definitions.md
  • Eslam M et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. PMID 32044314 — tags: [guideline, nomenclature] — cited by: nomenclature-and-definitions.md
  • Eslam M et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19(2):261-301. PMID 40016576 — tags: [guideline] — cited by: guidelines.md, nomenclature-and-definitions.md
  • European Association for the Study of the Liver (EASL) et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. PMID 38851997 — tags: [guideline] — cited by: guidelines.md, nomenclature-and-definitions.md
  • Fan JG et al. Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024). J Clin Transl Hepatol. 2024;12(11):955-974. PMID 39544247 — tags: [primary-research] — cited by: guidelines.md, nomenclature-and-definitions.md
  • Hagström H et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265-1273. PMID 28803953 — tags: [fibrosis, mortality] — cited by: clinical-trials-landscape.md, natural-history-and-fibrosis-progression.md, nomenclature-and-definitions.md, overview.md
  • Israelsen M et al. Steatotic liver disease. Lancet. 2024;404(10464):1761-1778. PMID 39488409 — tags: [review] — cited by: epidemiology-and-burden.md, nomenclature-and-definitions.md
  • Kalligeros M et al. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin Gastroenterol Hepatol. 2024;22(6):1330-1332.e4. PMID 37949334 — tags: [prevalence] — cited by: nomenclature-and-definitions.md
  • Kanwal F et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-1219. PMID 38445559 — tags: [nomenclature] — cited by: guidelines.md, nomenclature-and-definitions.md
  • Kim D et al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023. Clin Mol Hepatol. 2025;31(2):382-393. PMID 39610192 — tags: [fibrosis] — cited by: epidemiology-and-burden.md, nomenclature-and-definitions.md
  • Lee BP et al. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2024;79(3):666-673. PMID 37732946 — tags: [nomenclature, prevalence] — cited by: epidemiology-and-burden.md, nomenclature-and-definitions.md
  • Méndez-Sánchez N et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388-390. PMID 35248211 — tags: [editorial] — cited by: nomenclature-and-definitions.md
  • Ochoa-Allemant P et al. Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease. JAMA Intern Med. 2025;185(8):986-995. PMID 40522656 — tags: [cardiovascular, mortality] — cited by: cardiovascular-and-extrahepatic-outcomes.md, nomenclature-and-definitions.md, red-flags-and-safety-concerns.md
  • Rinella ME et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PMID 36727674 — tags: [primary-research] — cited by: guidelines.md, nomenclature-and-definitions.md
  • Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. PMID 37364790 — tags: [nomenclature, review] — cited by: nomenclature-and-definitions.md
  • Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PMID 37363821 — tags: [nomenclature] — cited by: nomenclature-and-definitions.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md
  • Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133. PMID 37364816 — tags: [nomenclature, review] — cited by: nomenclature-and-definitions.md
  • Song R et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44(4):1051-1060. PMID 38293788 — tags: [mortality] — cited by: epidemiology-and-burden.md, guidelines.md, nomenclature-and-definitions.md
  • Sripongpun P et al. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep. 2024;6(10):101127. PMID 39290401 — tags: [mortality] — cited by: nomenclature-and-definitions.md
  • Tilg H et al. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026;335(2):163-174. PMID 41212550 — tags: [review] — cited by: epidemiology-and-burden.md, masld-and-type-2-diabetes.md, nomenclature-and-definitions.md, overview.md, red-flags-and-safety-concerns.md
  • Younossi ZM et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80(5):694-701. PMID 38286339 — tags: [mortality] — cited by: nomenclature-and-definitions.md
  • Younossi ZM et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025;169(5):1017-1032.e2. PMID 40222485 — tags: [guideline] — cited by: guidelines.md, nomenclature-and-definitions.md
  • Zeng H et al. Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study. MedComm (2020). 2025;6(2):e70087. PMID 39949980 — tags: [nomenclature] — cited by: nomenclature-and-definitions.md, red-flags-and-safety-concerns.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Raverdy V, Tavaglione F, Chatelain E, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(12):3624-3633. PMID 39653777 — tags: [primary-research] — cited by: nomenclature-and-definitions.md, overview.md
  • Torp N, Bech KT, Schnefeld HL, et al. Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10(11):975-985. PMID 40945520 — tags: [cohort] — cited by: nomenclature-and-definitions.md, overview.md

Epidemiology, burden and projections

22 papers.

  • Amini-Salehi E et al. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries. Arch Med Res. 2024;55(6):103043. PMID 39094335 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, overview.md
  • Devarbhavi H et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516-537. PMID 36990226 — tags: [review] — cited by: epidemiology-and-burden.md
  • Duo T et al. Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections. Metabolism. 2026;178:156549. PMID 41643809 — tags: [primary-research] — cited by: cardiovascular-and-extrahepatic-outcomes.md, epidemiology-and-burden.md
  • En Li Cho E et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. PMID 37491159 — tags: [diabetes, meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, masld-and-type-2-diabetes.md
  • Estes C et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896-904. PMID 29886156 — tags: [primary-research] — cited by: epidemiology-and-burden.md
  • Estes C et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. PMID 28802062 — tags: [review] — cited by: epidemiology-and-burden.md
  • Feng G et al. Global Burden of Major Chronic Liver Diseases in 2021. Liver Int. 2025;45(4):e70058. PMID 40062742 — tags: [primary-research] — cited by: epidemiology-and-burden.md
  • Le MH et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841-850. PMID 36117442 — tags: [prevalence] — cited by: epidemiology-and-burden.md
  • Le MH et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28. PMID 34890795 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, overview.md
  • Le MH et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287-295. PMID 37040843 — tags: [meta-analysis] — cited by: epidemiology-and-burden.md
  • Le P et al. Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707. PMID 39821400 — tags: [primary-research] — cited by: cirrhosis-and-decompensation.md, epidemiology-and-burden.md, overview.md
  • Lee EJ et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr. 2024;20(6):569-580. PMID 38771552 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md
  • Li J et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389-398. PMID 30902670 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, masld-related-hepatocellular-carcinoma.md
  • Quek J et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. PMID 36400097 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, overview.md
  • Riazi K et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. PMID 35798021 — tags: [meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, overview.md
  • Vilar-Gomez E et al. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. Clin Gastroenterol Hepatol. 2023;21(1):115-124.e7. PMID 34958922 — tags: [prevalence] — cited by: epidemiology-and-burden.md, masld-and-type-2-diabetes.md
  • Wong VW et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842-852. PMID 37169151 — tags: [prevalence, review] — cited by: epidemiology-and-burden.md
  • Ye Q et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739-752. PMID 32413340 — tags: [lean, meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, lean-masld.md, overview.md
  • Younossi ZM et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. PMID 36626630 — tags: [meta-analysis, prevalence] — cited by: cardiovascular-and-extrahepatic-outcomes.md, epidemiology-and-burden.md, natural-history-and-fibrosis-progression.md, overview.md
  • Younossi ZM et al. Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010-2021). Liver Int. 2025;45(10):e70342. PMID 40919841 — tags: [primary-research] — cited by: epidemiology-and-burden.md
  • Zamani M et al. Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025;23(7):1123-1134. PMID 39209202 — tags: [cirrhosis, fibrosis, meta-analysis, prevalence] — cited by: epidemiology-and-burden.md, overview.md
  • Zhou J et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71(5):1851-1864. PMID 32012320 — tags: [prevalence, systematic-review] — cited by: epidemiology-and-burden.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023;35(3):414-428.e3. PMID 36889281 — tags: [primary-research] — cited by: epidemiology-and-burden.md
  • Shalimar, Elhence A, Bansal B, et al. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. J Clin Exp Hepatol. 2022;12(3):818-829. PMID 35677499 — tags: [meta-analysis, systematic-review] — cited by: epidemiology-and-burden.md, guidelines.md
  • Zhang H, Zhou XD, Shapiro MD, et al. Global burden of metabolic diseases, 1990-2021. Metabolism. 2024;160:155999. PMID 39151887 — tags: [primary-research] — cited by: epidemiology-and-burden.md

Pathogenesis and mechanism

23 papers.

  • Aron-Wisnewsky J et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279-297. PMID 32152478 — tags: [microbiome, review] — cited by: pathogenesis.md
  • Buzzetti E et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. PMID 26823198 — tags: [review] — cited by: overview.md, pathogenesis.md
  • Deczkowska A et al. XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med. 2021;27(6):1043-1054. PMID 34017133 — tags: [primary-research] — cited by: pathogenesis.md
  • Demir M et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022;76(4):788-799. PMID 34896404 — tags: [primary-research] — cited by: pathogenesis.md
  • Donnelly KL et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-51. PMID 15864352 — tags: [primary-research] — cited by: overview.md, pathogenesis.md
  • Govaere O et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat Metab. 2023;5(4):572-578. PMID 37037945 — tags: [cohort] — cited by: pathogenesis.md
  • Hou J et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest. 2021;131(4). PMID 33586673 — tags: [primary-research] — cited by: pathogenesis.md
  • Kisseleva T et al. Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis. Gastroenterology. 2025;169(5):797-812. PMID 40120772 — tags: [review] — cited by: pathogenesis.md
  • Koliaki C et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739-46. PMID 25955209 — tags: [primary-research] — cited by: overview.md, pathogenesis.md
  • Lee E et al. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78(5):1048-1062. PMID 36740049 — tags: [review] — cited by: pathogenesis.md
  • Loomba R et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25(5):1054-1062.e5. PMID 28467925 — tags: [fibrosis, genetics, microbiome] — cited by: pathogenesis.md
  • Loomba R et al. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. PMID 33989548 — tags: [review] — cited by: pathogenesis.md
  • Marra F et al. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280-295. PMID 29154964 — tags: [review] — cited by: overview.md, pathogenesis.md
  • Martin OP et al. Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis. Nat Immunol. 2025;26(9):1596-1611. PMID 40883571 — tags: [primary-research] — cited by: pathogenesis.md
  • Mouries J et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216-1228. PMID 31419514 — tags: [microbiome] — cited by: pathogenesis.md
  • Oh TG et al. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab. 2020;32(5):878-888.e6. PMID 32610095 — tags: [cirrhosis, microbiome] — cited by: pathogenesis.md
  • Remmerie A et al. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity. 2020;53(3):641-657.e14. PMID 32888418 — tags: [primary-research] — cited by: pathogenesis.md
  • Schwabe RF et al. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology. 2020;158(7):1913-1928. PMID 32044315 — tags: [fibrosis, review] — cited by: overview.md, pathogenesis.md
  • Steinberg GR et al. MASH: the nexus of metabolism, inflammation, and fibrosis. J Clin Invest. 2025;135(18). PMID 40955659 — tags: [fibrosis, review] — cited by: pathogenesis.md
  • Steinberg GR et al. Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms. J Hepatol. 2025;83(2):584-595. PMID 40032040 — tags: [review] — cited by: pathogenesis.md
  • Tilg H et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596-1607. PMID 34931080 — tags: [review] — cited by: pathogenesis.md
  • Todoric J et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034-1045. PMID 32839596 — tags: [primary-research] — cited by: pathogenesis.md
  • Yki-Järvinen H et al. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2021;18(11):770-786. PMID 34257427 — tags: [review] — cited by: lifestyle-and-weight-loss.md, pathogenesis.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Chaurasia B, Tippetts TS, Mayoral Monibas R, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365(6451):386-392. PMID 31273070 — tags: [primary-research] — cited by: pathogenesis.md
  • Chen B, Sun L, Zeng G, et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 2022;610(7932):562-568. PMID 36261549 — tags: [primary-research] — cited by: pathogenesis.md
  • Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2018;27(1):22-41. PMID 28867301 — tags: [primary-research] — cited by: pathogenesis.md

Genetics and precision medicine

16 papers.

  • Abul-Husn NS et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378(12):1096-1106. PMID 29562163 — tags: [hsd17b13] — cited by: genetics.md, overview.md
  • Anstee QM et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆). J Hepatol. 2020;73(3):505-515. PMID 32298765 — tags: [cohort, genetics, histology] — cited by: genetics.md
  • Armisen J et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials. J Hepatol. 2025;83(1):31-42. PMID 39798707 — tags: [pnpla3, trial] — cited by: clinical-trials-landscape.md, genetics.md
  • Bianco C et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74(4):775-782. PMID 33248170 — tags: [hcc] — cited by: genetics.md, masld-related-hepatocellular-carcinoma.md
  • Chen VL et al. PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis. Gastroenterology. 2023;164(6):966-977.e17. PMID 36758837 — tags: [cirrhosis, diabetes, pnpla3] — cited by: genetics.md
  • Chen VL et al. Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort. J Hepatol. 2024;81(3):379-388. PMID 38582304 — tags: [fibrosis, genetics] — cited by: genetics.md, lifestyle-and-weight-loss.md
  • Chen Y et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet. 2023;55(10):1640-1650. PMID 37709864 — tags: [genetics, meta-analysis] — cited by: genetics.md
  • Cherubini A et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2023;29(10):2643-2655. PMID 37749332 — tags: [pnpla3] — cited by: genetics.md
  • Cui J et al. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology. 2016;64(5):1547-1558. PMID 27315352 — tags: [fibrosis, genetics, twin-study] — cited by: genetics.md
  • Díaz LA et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J Hepatol. 2025;83(4):849-859. PMID 40334848 — tags: [fibrosis] — cited by: genetics.md
  • Fabbrini E et al. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. N Engl J Med. 2024;391(5):475-476. PMID 39083780 — tags: [editorial, pnpla3, trial] — cited by: genetics.md
  • Lindén D et al. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J Hepatol. 2023;79(4):1056-1064. PMID 37207913 — tags: [genetics, review] — cited by: genetics.md
  • Loomba R et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015;149(7):1784-93. PMID 26299412 — tags: [fibrosis, twin-study] — cited by: genetics.md, overview.md
  • Romeo S et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5. PMID 18820647 — tags: [genetics, pnpla3] — cited by: genetics.md, overview.md
  • Sanyal AJ et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83(4):838-848. PMID 40581300 — tags: [cohort, hsd17b13, trial] — cited by: clinical-trials-landscape.md, genetics.md
  • Vilar-Gomez E et al. Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. 2026;84(3):502-516. PMID 40998180 — tags: [genetics, histology] — cited by: genetics.md, natural-history-and-fibrosis-progression.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Ghouse J, Sveinbjörnsson G, Vujkovic M, et al. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat Genet. 2024;56(5):827-837. PMID 38632349 — tags: [primary-research] — cited by: genetics.md
  • Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54(11):1652-1663. PMID 36280732 — tags: [primary-research] — cited by: genetics.md
  • Verweij N, Haas ME, Nielsen JB, et al. Germline Mutations in CIDEB and Protection against Liver Disease. N Engl J Med. 2022;387(4):332-344. PMID 35939579 — tags: [primary-research] — cited by: genetics.md
  • Wong WJ, Emdin C, Bick AG, et al. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023;616(7958):747-754. PMID 37046084 — tags: [primary-research] — cited by: genetics.md

Non-invasive assessment and risk stratification

20 papers.

  • Ajmera V et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471-478. PMID 36410554 — tags: [cirrhosis, diabetes, fibrosis, hcc, prevalence] — cited by: masld-and-type-2-diabetes.md, noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Caussy C et al. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025;48(6):877-886. PMID 39887699 — tags: [cohort, diabetes, fibrosis] — cited by: masld-and-type-2-diabetes.md, noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Daniels SJ et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019;69(3):1075-1086. PMID 30014517 — tags: [fibrosis] — cited by: noninvasive-assessment.md
  • Eddowes PJ et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717-1730. PMID 30689971 — tags: [fibrosis] — cited by: noninvasive-assessment.md
  • Kanwal F et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-1669. PMID 34602251 — tags: [guideline] — cited by: guidelines.md, noninvasive-assessment.md
  • Kjaergaard M et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277-286. PMID 37088311 — tags: [fib-4, fibrosis, trial] — cited by: noninvasive-assessment.md
  • Lazarus JV et al. Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes. JAMA Netw Open. 2025;8(11):e2542750. PMID 41196592 — tags: [diabetes] — cited by: masld-and-type-2-diabetes.md, noninvasive-assessment.md
  • Lin H et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331(15):1287-1297. PMID 38512249 — tags: [elastography] — cited by: cirrhosis-and-decompensation.md, guidelines.md, natural-history-and-fibrosis-progression.md, noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Lindvig KP et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10(1):55-67. PMID 39674225 — tags: [fibrosis] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Mózes FE et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-1019. PMID 34001645 — tags: [fibrosis, meta-analysis] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Mózes FE et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704-713. PMID 37290471 — tags: [histology, meta-analysis] — cited by: clinical-trials-landscape.md, natural-history-and-fibrosis-progression.md, noninvasive-assessment.md, overview.md
  • Newsome PN et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-373. PMID 32027858 — tags: [cohort, fibrosis, trial] — cited by: noninvasive-assessment.md
  • Sanyal AJ et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78(2):247-259. PMID 36375686 — tags: [cirrhosis, fibrosis] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Sanyal AJ et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29(10):2656-2664. PMID 37679433 — tags: [primary-research] — cited by: noninvasive-assessment.md
  • Selvaraj EA et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75(4):770-785. PMID 33991635 — tags: [elastography, meta-analysis] — cited by: noninvasive-assessment.md
  • Sripongpun P et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology. 2023;77(1):256-267. PMID 35477908 — tags: [cohort, fibrosis] — cited by: noninvasive-assessment.md
  • Tsochatzis EA. Screening for liver fibrosis - sequential non-invasive testing works best. J Hepatol. 2023;79(2):263-265. PMID 37295681 — tags: [editorial, fibrosis] — cited by: noninvasive-assessment.md
  • van Kleef LA et al. Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction. Gastroenterology. 2024;167(2):357-367.e9. PMID 38513745 — tags: [fibrosis] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Wattacheril JJ et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023;165(4):1080-1088. PMID 37542503 — tags: [guideline] — cited by: guidelines.md, histology-and-biopsy.md, noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Younossi ZM et al. Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. Hepatology. 2026;84(1):161-174. PMID 41100867 — tags: [cohort] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md, resmetirom-and-thyromimetics.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Charu V, Liang JW, Mannalithara A, et al. Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD. Hepatology. 2024;80(5):1184-1195. PMID 38687634 — tags: [primary-research] — cited by: noninvasive-assessment.md
  • Graupera I, Thiele M, Serra-Burriel M, et al. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2022;20(11):2567-2576.e6. PMID 34971806 — tags: [primary-research] — cited by: noninvasive-assessment.md
  • McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112(5):740-751. PMID 27725647 — tags: [primary-research] — cited by: noninvasive-assessment.md
  • Verschuren L, Mak AL, van Koppen A, et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nat Commun. 2024;15(1):4564. PMID 38811591 — tags: [primary-research] — cited by: noninvasive-assessment.md

Histology, scoring systems and digital pathology

12 papers.

  • Akbari C et al. Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. JHEP Rep. 2024;6(2):100915. PMID 38293684 — tags: [cirrhosis] — cited by: clinical-trials-landscape.md, histology-and-biopsy.md, natural-history-and-fibrosis-progression.md, overview.md
  • Bedossa P et al. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565-75. PMID 24753132 — tags: [fibrosis] — cited by: histology-and-biopsy.md
  • Brunt EM et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810-20. PMID 21319198 — tags: [primary-research] — cited by: clinical-trials-landscape.md, histology-and-biopsy.md
  • Brunt EM et al. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021;73(5):2028-2038. PMID 33111374 — tags: [histology, review] — cited by: cirrhosis-and-decompensation.md, histology-and-biopsy.md, red-flags-and-safety-concerns.md
  • Fujiwara N et al. AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83(3):575-590. PMID 40262132 — tags: [primary-research] — cited by: histology-and-biopsy.md, masld-related-hepatocellular-carcinoma.md
  • Hagström H et al. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand J Gastroenterol. 2017;52(1):87-91. PMID 27616339 — tags: [mortality] — cited by: histology-and-biopsy.md
  • Kleiner DE et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. PMID 15915461 — tags: [cohort, histology] — cited by: clinical-trials-landscape.md, histology-and-biopsy.md, overview.md
  • Li YY et al. Hepatocytic ballooning in non-alcoholic steatohepatitis: Dilemmas and future directions. Liver Int. 2023;43(6):1170-1182. PMID 37017559 — tags: [review] — cited by: histology-and-biopsy.md
  • Nakatsuka T et al. Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease. Hepatology. 2025;81(3):976-989. PMID 38768142 — tags: [primary-research] — cited by: histology-and-biopsy.md, masld-related-hepatocellular-carcinoma.md
  • Nascimbeni F et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol. 2020;72(5):828-838. PMID 31862486 — tags: [primary-research] — cited by: histology-and-biopsy.md
  • Sanyal AJ et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559-1569. PMID 34670043 — tags: [cohort] — cited by: cardiovascular-and-extrahepatic-outcomes.md, histology-and-biopsy.md, masld-related-hepatocellular-carcinoma.md
  • Sanyal AJ et al. Digital pathology for nonalcoholic steatohepatitis assessment. Nat Rev Gastroenterol Hepatol. 2024;21(1):57-69. PMID 37789057 — tags: [review] — cited by: clinical-trials-landscape.md, histology-and-biopsy.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73(6):1322-1332. PMID 32610115 — tags: [randomised-trial] — cited by: histology-and-biopsy.md
  • Harrison SA, Dubourg J. Liver biopsy evaluation in MASH drug development: Think thrice, act wise. J Hepatol. 2024;81(5):886-894. PMID 38879176 — tags: [primary-research] — cited by: histology-and-biopsy.md
  • Pulaski H, Harrison SA, Mehta SS, et al. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31(1):315-322. PMID 39496972 — tags: [primary-research] — cited by: histology-and-biopsy.md
  • Ratziu V, Bugianesi E, Dixon J, et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther. 2007;26(6):821-30. PMID 17767466 — tags: [primary-research] — cited by: histology-and-biopsy.md
  • Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-906. PMID 15940625 — tags: [primary-research] — cited by: histology-and-biopsy.md

Natural history, fibrosis progression and outcomes

12 papers.

  • Dulai PS et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-1565. PMID 28130788 — tags: [fibrosis, meta-analysis, mortality] — cited by: natural-history-and-fibrosis-progression.md, overview.md
  • Ekstedt M et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-54. PMID 25125077 — tags: [fibrosis, mortality] — cited by: natural-history-and-fibrosis-progression.md
  • Fujii H et al. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clin Gastroenterol Hepatol. 2023;21(2):370-379. PMID 35051649 — tags: [cohort] — cited by: cardiovascular-and-extrahepatic-outcomes.md, natural-history-and-fibrosis-progression.md
  • Hagström H et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944-956. PMID 39243773 — tags: [review] — cited by: natural-history-and-fibrosis-progression.md, overview.md
  • Iwaki M et al. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study. Clin Mol Hepatol. 2024;30(2):225-234. PMID 38263684 — tags: [cohort] — cited by: natural-history-and-fibrosis-progression.md
  • Le MH et al. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(2):235-246. PMID 38281814 — tags: [meta-analysis] — cited by: masld-and-type-2-diabetes.md, masld-related-hepatocellular-carcinoma.md, natural-history-and-fibrosis-progression.md
  • Ng CH et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931-939.e5. PMID 35513235 — tags: [fibrosis, meta-analysis, mortality] — cited by: natural-history-and-fibrosis-progression.md
  • Noureddin N et al. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(12):1521-1526. PMID 38571305 — tags: [primary-research] — cited by: cirrhosis-and-decompensation.md, natural-history-and-fibrosis-progression.md, overview.md, red-flags-and-safety-concerns.md
  • Simon TG et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375-1382. PMID 33037056 — tags: [mortality] — cited by: cardiovascular-and-extrahepatic-outcomes.md, natural-history-and-fibrosis-progression.md, overview.md
  • Singh S et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54.e1-9; quiz e39-40. PMID 24768810 — tags: [fibrosis, meta-analysis] — cited by: natural-history-and-fibrosis-progression.md, overview.md
  • Taylor RS et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-1625.e12. PMID 32027911 — tags: [fibrosis, meta-analysis] — cited by: clinical-trials-landscape.md, natural-history-and-fibrosis-progression.md, overview.md
  • Younossi ZM et al. Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study. Hepatology. 2026;84(1):204-215. PMID 41231627 — tags: [fibrosis, mortality] — cited by: masld-and-type-2-diabetes.md, natural-history-and-fibrosis-progression.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Celsa C, Pennisi G, Tulone A, et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(11):998-1012. PMID 40953570 — tags: [meta-analysis, systematic-review] — cited by: natural-history-and-fibrosis-progression.md
  • Kwak M, Kim HS, Jiang ZG, et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up. Hepatology. 2025;81(1):228-237. PMID 38739848 — tags: [primary-research] — cited by: natural-history-and-fibrosis-progression.md, overview.md
  • Miwa T, Díaz LA, Harberts A, et al. Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis. Aliment Pharmacol Ther. 2026;64(3):367-378. PMID 42120953 — tags: [primary-research] — cited by: natural-history-and-fibrosis-progression.md

Lifestyle, diet and exercise

8 papers.

  • Ezpeleta M et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab. 2023;35(1):56-70.e3. PMID 36549296 — tags: [trial] — cited by: lifestyle-and-weight-loss.md
  • Jayabalan D et al. The Impact of Body Weight Change on Liver Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Across Various Histological Endpoints: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026. PMID 41510965 — tags: [histology] — cited by: lifestyle-and-weight-loss.md
  • Lange M et al. Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Hepatol Commun. 2023;7(8). PMID 37534936 — tags: [meta-analysis] — cited by: lifestyle-and-weight-loss.md
  • Mucinski JM et al. Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH. J Hepatol. 2024;81(5):781-793. PMID 38914313 — tags: [histology, trial] — cited by: lifestyle-and-weight-loss.md
  • Romero-Gómez M et al. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846. PMID 28545937 — tags: [review] — cited by: lifestyle-and-weight-loss.md
  • Vilar-Gomez E et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-78.e5; quiz e14-5. PMID 25865049 — tags: [primary-research] — cited by: bariatric-and-metabolic-surgery.md, lifestyle-and-weight-loss.md, overview.md
  • Yaskolka Meir A et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021;70(11):2085-2095. PMID 33461965 — tags: [trial] — cited by: lifestyle-and-weight-loss.md
  • Younossi ZM et al. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2021;160(3):912-918. PMID 33307021 — tags: [guideline] — cited by: guidelines.md, lifestyle-and-weight-loss.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Arita VA, Cabezas MC, Hernández Vargas JA, et al. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2025;23(1):502. PMID 40866968 — tags: [meta-analysis, systematic-review, randomised-trial] — cited by: lifestyle-and-weight-loss.md
  • Callans LE, Ivey KL, Chang KM, et al. Diet composition impacts the natural history of steatotic liver disease. Hepatol Commun. 2025;9(7):e0754. PMID 40536509 — tags: [primary-research] — cited by: lifestyle-and-weight-loss.md
  • Chen YP, Lu FB, Hu YB, et al. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552-2557. PMID 30573353 — tags: [meta-analysis, systematic-review] — cited by: lifestyle-and-weight-loss.md
  • Ebadi M, Ip S, Bhanji RA, et al. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients. 2021;13(9):3042. PMID 34578919 — tags: [meta-analysis, systematic-review] — cited by: lifestyle-and-weight-loss.md
  • George ES, Reddy A, Nicoll AJ, et al. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial. Liver Int. 2022;42(6):1308-1322. PMID 35357066 — tags: [randomised-trial] — cited by: lifestyle-and-weight-loss.md

Resmetirom and thyroid hormone receptor-β agonists

8 papers.

  • Harrison SA et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012-2024. PMID 31727409 — tags: [cohort, resmetirom, trial] — cited by: resmetirom-and-thyromimetics.md
  • Harrison SA et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-2928. PMID 37845512 — tags: [resmetirom, trial] — cited by: resmetirom-and-thyromimetics.md
  • Harrison SA et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID 38324483 — tags: [fibrosis, resmetirom, trial] — cited by: bariatric-and-metabolic-surgery.md, clinical-trials-landscape.md, overview.md, red-flags-and-safety-concerns.md, resmetirom-and-thyromimetics.md
  • Keam SJ. Resmetirom: First Approval. Drugs. 2024;84(6):729-735. PMID 38771485 — tags: [resmetirom] — cited by: overview.md, resmetirom-and-thyromimetics.md
  • Noureddin M et al. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024;22(12):2367-2377. PMID 39038768 — tags: [cirrhosis, fibrosis, resmetirom, review] — cited by: cirrhosis-and-decompensation.md, guidelines.md, red-flags-and-safety-concerns.md, resmetirom-and-thyromimetics.md
  • Noureddin M et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025;62(11-12):1089-1099. PMID 41127972 — tags: [cohort, diabetes, resmetirom, trial] — cited by: masld-and-type-2-diabetes.md, resmetirom-and-thyromimetics.md
  • Ratziu V et al. Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol. 2025;82(2):375-387. PMID 39428045 — tags: [review] — cited by: resmetirom-and-thyromimetics.md
  • Souza M et al. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Hepatology. 2025;82(6):1523-1533. PMID 39903735 — tags: [fibrosis, meta-analysis] — cited by: clinical-trials-landscape.md, glp1-and-incretin-therapy.md, other-pharmacotherapy.md, resmetirom-and-thyromimetics.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Amdetsion GY, Pan CW, Tebeje H, et al. Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta-Analysis. Int J Hepatol. 2025;2025:8133686. PMID 41357781 — tags: [meta-analysis, systematic-review] — cited by: resmetirom-and-thyromimetics.md
  • Han X, Ai X, Sun Y, et al. Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. 2026;38(4):407-415. PMID 41811770 — tags: [meta-analysis, systematic-review, network-meta-analysis] — cited by: resmetirom-and-thyromimetics.md
  • Harrison SA, Bashir M, Moussa SE, et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun. 2021;5(4):573-588. PMID 33860116 — tags: [primary-research] — cited by: resmetirom-and-thyromimetics.md
  • Javanbakht M, Fishman J, Moloney E, et al. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. Pharmacoecon Open. 2023;7(1):93-110. PMID 36104546 — tags: [health-economics] — cited by: resmetirom-and-thyromimetics.md
  • Le P, Dasarathy S, Herman WH, et al. Value-Based Pricing of Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Netw Open. 2025;8(6):e2517122. PMID 40577015 — tags: [health-economics] — cited by: resmetirom-and-thyromimetics.md
  • Mantovani A, Csermely A, Bilson J, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut. 2024;73(9):1554-1561. PMID 38782564 — tags: [meta-analysis] — cited by: resmetirom-and-thyromimetics.md
  • Schattenberg JM, Bedossa P, Guy CD, et al. Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. J Hepatol. 2026;85(2):202-211. PMID 41895606 — tags: [primary-research] — cited by: resmetirom-and-thyromimetics.md
  • Shuaibi S, Tobal I, Gore J, et al. A Real-World Experience With Resmetirom: Tolerability and Access. Gastro Hep Adv. 2025;4(9):100709. PMID 40688390 — tags: [primary-research] — cited by: resmetirom-and-thyromimetics.md
  • Yuan S, Ebrahimi F, Bergman D, et al. Thyroid dysfunction in MASLD: Results of a nationwide study. JHEP Rep. 2025;7(5):101369. PMID 40342634 — tags: [primary-research] — cited by: resmetirom-and-thyromimetics.md
  • Zhang YH, Xie R, Dai CS, et al. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. 2025;82(2):189-202. PMID 39181210 — tags: [primary-research] — cited by: resmetirom-and-thyromimetics.md

GLP-1 receptor agonists and incretin multi-agonists

13 papers.

  • Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. PMID 26608256 — tags: [cohort, lean, trial] — cited by: glp1-and-incretin-therapy.md
  • Bansal MB et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. PMID 41201884 — tags: [guideline, semaglutide] — cited by: glp1-and-incretin-therapy.md, guidelines.md, overview.md, red-flags-and-safety-concerns.md
  • Harrison SA et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7-17. PMID 39002641 — tags: [cohort, incretin, trial] — cited by: glp1-and-incretin-therapy.md
  • Loomba R et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. PMID 36934740 — tags: [cirrhosis, semaglutide, trial] — cited by: cirrhosis-and-decompensation.md, glp1-and-incretin-therapy.md
  • Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PMID 38856224 — tags: [cohort, fibrosis, incretin, trial] — cited by: clinical-trials-landscape.md, glp1-and-incretin-therapy.md
  • Mantovani A et al. Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials. Liver Int. 2025;45(9):e70256. PMID 40736113 — tags: [fibrosis, meta-analysis] — cited by: glp1-and-incretin-therapy.md
  • Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID 33185364 — tags: [cohort, semaglutide, trial] — cited by: glp1-and-incretin-therapy.md, red-flags-and-safety-concerns.md
  • Newsome PN et al. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023;79(6):1557-1565. PMID 37562748 — tags: [incretin, review] — cited by: glp1-and-incretin-therapy.md
  • Noureddin M et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025;392(24):2413-2424. PMID 40341827 — tags: [cirrhosis, cohort, fgf21, trial] — cited by: cirrhosis-and-decompensation.md, clinical-trials-landscape.md, glp1-and-incretin-therapy.md, other-pharmacotherapy.md
  • Romero-Gómez M et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79(4):888-897. PMID 37355043 — tags: [trial] — cited by: glp1-and-incretin-therapy.md
  • Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PMID 38847460 — tags: [cohort, fibrosis, incretin, trial] — cited by: clinical-trials-landscape.md, glp1-and-incretin-therapy.md
  • Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523 — tags: [trial] — cited by: glp1-and-incretin-therapy.md
  • Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID 40305708 — tags: [cohort, semaglutide, trial] — cited by: bariatric-and-metabolic-surgery.md, clinical-trials-landscape.md, glp1-and-incretin-therapy.md, overview.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Choi J, Kamath T, Nguyen VH, et al. GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching. Liver Int. 2025;45(12):e70447. PMID 41250965 — tags: [target-trial-emulation] — cited by: glp1-and-incretin-therapy.md
  • Henney AE, Riley DR, Anson M, et al. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver Int. 2025;45(10):e70367. PMID 40980971 — tags: [target-trial-emulation] — cited by: glp1-and-incretin-therapy.md
  • Karakasis P, Patoulias D, Fragakis N, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. PMID 39719170 — tags: [meta-analysis, systematic-review, network-meta-analysis] — cited by: glp1-and-incretin-therapy.md
  • Kuo CC, Li CH, Chuang MH, et al. Semaglutide versus other GLP-1 receptor agonists in patients with MASLD. Hepatol Commun. 2025;9(7):e0747. PMID 40536520 — tags: [primary-research] — cited by: glp1-and-incretin-therapy.md

Bariatric and metabolic surgery

4 papers.

  • Aminian A et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021;326(20):2031-2042. PMID 34762106 — tags: [bariatric, cardiovascular, cohort] — cited by: bariatric-and-metabolic-surgery.md, cardiovascular-and-extrahepatic-outcomes.md, overview.md, red-flags-and-safety-concerns.md
  • Lassailly G et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301.e5. PMID 32553765 — tags: [bariatric, fibrosis] — cited by: bariatric-and-metabolic-surgery.md, overview.md
  • Lefere S et al. Bariatric surgery and the liver-Mechanisms, benefits, and risks. Obes Rev. 2021;22(9):e13294. PMID 34002452 — tags: [bariatric, review] — cited by: bariatric-and-metabolic-surgery.md, cirrhosis-and-decompensation.md, red-flags-and-safety-concerns.md
  • Verrastro O et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786-1797. PMID 37088093 — tags: [bariatric, cohort, trial] — cited by: bariatric-and-metabolic-surgery.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Aminian A, Aljabri A, Wang S, et al. Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31(3):988-995. PMID 39870816 — tags: [primary-research] — cited by: bariatric-and-metabolic-surgery.md
  • Bramming M, Becker U, Jørgensen MB, et al. Bariatric surgery and risk of alcohol use disorder: a register-based cohort study. Int J Epidemiol. 2021;49(6):1826-1835. PMID 33085738 — tags: [cohort] — cited by: bariatric-and-metabolic-surgery.md
  • Fakhoury B, Sierra L, Rama K, et al. Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder. JAMA Netw Open. 2025;8(12):e2549086. PMID 41632137 — tags: [primary-research] — cited by: bariatric-and-metabolic-surgery.md
  • Sjöholm K, Peltonen M, Jacobson P, et al. Alcohol use disorder and alcohol-related mortality after metabolic bariatric surgery: prospective controlled cohort study. Br J Surg. 2025;112(10):znaf211. PMID 41066138 — tags: [cohort] — cited by: bariatric-and-metabolic-surgery.md

Other pharmacotherapy and failed agents

17 papers.

  • Bril F et al. Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence. Diabetes Obes Metab. 2023;25(4):1112-1116. PMID 36495442 — tags: [primary-research] — cited by: other-pharmacotherapy.md, red-flags-and-safety-concerns.md
  • Cusi K et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-15. PMID 27322798 — tags: [diabetes, trial] — cited by: masld-and-type-2-diabetes.md, other-pharmacotherapy.md, red-flags-and-safety-concerns.md
  • Francque SM et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547-1558. PMID 34670042 — tags: [cohort, trial] — cited by: clinical-trials-landscape.md, other-pharmacotherapy.md
  • Friedman SL et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754-1767. PMID 28833331 — tags: [cohort, fibrosis, trial] — cited by: other-pharmacotherapy.md
  • Harrison SA et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26-39. PMID 32147362 — tags: [cirrhosis, fibrosis, trial] — cited by: cirrhosis-and-decompensation.md, clinical-trials-landscape.md, other-pharmacotherapy.md
  • Jang H et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2024;184(4):375-383. PMID 38345802 — tags: [cohort, diabetes] — cited by: masld-and-type-2-diabetes.md, other-pharmacotherapy.md
  • Lavine JE et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659-68. PMID 21521847 — tags: [cohort, trial] — cited by: other-pharmacotherapy.md
  • Loomba R et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998-1008. PMID 37356033 — tags: [cohort, fgf21, trial] — cited by: clinical-trials-landscape.md, other-pharmacotherapy.md
  • Loomba R et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024;9(12):1090-1100. PMID 39396529 — tags: [cohort, trial] — cited by: clinical-trials-landscape.md, other-pharmacotherapy.md
  • Mao X et al. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut. 2024;73(12):2054-2061. PMID 39122360 — tags: [diabetes] — cited by: masld-and-type-2-diabetes.md, masld-related-hepatocellular-carcinoma.md, other-pharmacotherapy.md
  • Noureddin M et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025;406(10504):719-730. PMID 40818852 — tags: [cohort, fgf21, trial] — cited by: clinical-trials-landscape.md, other-pharmacotherapy.md
  • Ratziu V et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021;27(10):1825-1835. PMID 34621052 — tags: [trial] — cited by: other-pharmacotherapy.md
  • Sanyal AJ et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85. PMID 20427778 — tags: [cohort, trial] — cited by: other-pharmacotherapy.md
  • Vilar-Gomez E et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2020;71(2):495-509. PMID 30506586 — tags: [fibrosis] — cited by: cirrhosis-and-decompensation.md, other-pharmacotherapy.md
  • Wen H et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10(10):CD015033. PMID 39412049 — tags: [meta-analysis] — cited by: other-pharmacotherapy.md
  • Younossi ZM et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-2196. PMID 31813633 — tags: [cohort, trial] — cited by: clinical-trials-landscape.md, other-pharmacotherapy.md, red-flags-and-safety-concerns.md
  • Zhou XD et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883-1892. PMID 39089860 — tags: [cohort, statins] — cited by: cardiovascular-and-extrahepatic-outcomes.md, other-pharmacotherapy.md, red-flags-and-safety-concerns.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Cheung KS, Ng HY, Hui RWH, et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Hepatology. 2024;80(4):916-927. PMID 38536017 — tags: [randomised-trial] — cited by: other-pharmacotherapy.md
  • Kuchay MS, Krishan S, Mishra SK, et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801-1808. PMID 29895557 — tags: [randomised-trial] — cited by: other-pharmacotherapy.md
  • Loomba R, Noureddin M, Kowdley KV, et al. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021;73(2):625-643. PMID 33169409 — tags: [primary-research] — cited by: other-pharmacotherapy.md

Cirrhosis, portal hypertension, decompensation and transplant

7 papers.

  • Aceituno L et al. The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease. Gastroenterology. 2026;170(2):385-394. PMID 41212130 — tags: [cohort, histology] — cited by: cirrhosis-and-decompensation.md, clinical-trials-landscape.md, guidelines.md, overview.md
  • Kanwal F et al. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024;184(11):1314-1323. PMID 39283612 — tags: [cirrhosis, incretin] — cited by: cirrhosis-and-decompensation.md, glp1-and-incretin-therapy.md, masld-and-type-2-diabetes.md, masld-related-hepatocellular-carcinoma.md
  • Lim WH et al. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023;79(4):1015-1024. PMID 37307997 — tags: [cirrhosis] — cited by: cardiovascular-and-extrahepatic-outcomes.md, cirrhosis-and-decompensation.md
  • Liu WY et al. From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective. Gastroenterology. 2025;169(2):326-336.e4. PMID 40113099 — tags: [cohort] — cited by: cirrhosis-and-decompensation.md, red-flags-and-safety-concerns.md
  • Paternostro R et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J Hepatol. 2024;81(5):827-836. PMID 38823501 — tags: [cohort, mortality] — cited by: cirrhosis-and-decompensation.md, red-flags-and-safety-concerns.md
  • Pennisi G et al. Impact of first and further decompensation in patients with compensated ACLD due to MASLD. J Hepatol. 2025;83(6):1266-1277. PMID 40550340 — tags: [cohort] — cited by: cardiovascular-and-extrahepatic-outcomes.md, cirrhosis-and-decompensation.md, red-flags-and-safety-concerns.md
  • Premkumar M et al. Recompensation in decompensated cirrhosis. Lancet Gastroenterol Hepatol. 2025;10(11):1028-1040. PMID 40780235 — tags: [cirrhosis, review] — cited by: cirrhosis-and-decompensation.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Bañares J, Pons M, Reiberger T, et al. Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis. J Hepatol. 2026;84(3):543-553. PMID 41138818 — tags: [meta-analysis] — cited by: cirrhosis-and-decompensation.md
  • Jachs M, Odriozola A, Turon F, et al. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study. Lancet Gastroenterol Hepatol. 2024;9(12):1111-1120. PMID 39326431 — tags: [primary-research] — cited by: cirrhosis-and-decompensation.md
  • Odriozola A, Puente Á, Cuadrado A, et al. High accuracy of spleen stiffness measurement in diagnosing clinically significant portal hypertension in metabolic-associated fatty liver disease. Liver Int. 2023;43(7):1446-1457. PMID 36912787 — tags: [primary-research] — cited by: cirrhosis-and-decompensation.md

7 papers.

  • Crane H et al. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(3):436-448. PMID 38623613 — tags: [hcc, meta-analysis, prevalence] — cited by: masld-related-hepatocellular-carcinoma.md
  • Fujiwara N et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med. 2022;14(650):eabo4474. PMID 35731891 — tags: [hcc] — cited by: masld-related-hepatocellular-carcinoma.md
  • Huang DQ et al. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. PMID 33349658 — tags: [prevalence, review] — cited by: masld-related-hepatocellular-carcinoma.md, red-flags-and-safety-concerns.md
  • John BV et al. Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83(6):1456-1468. PMID 40810411 — tags: [primary-research] — cited by: masld-related-hepatocellular-carcinoma.md
  • Machado MV. Hepatocellular carcinoma screening in NAFLD: The paradox of nearly half the cases arising in non-cirrhotic low risk patients. Ann Hepatol. 2023;28(3):101101. PMID 37116966 — tags: [cirrhosis, editorial, hcc] — cited by: masld-related-hepatocellular-carcinoma.md
  • Pfister D et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450-456. PMID 33762733 — tags: [primary-research] — cited by: masld-related-hepatocellular-carcinoma.md
  • Tan DJH et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521-530. PMID 35255263 — tags: [hcc, meta-analysis] — cited by: masld-related-hepatocellular-carcinoma.md, red-flags-and-safety-concerns.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Ahn J, Hur MH, Shin H, et al. Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis. Clin Mol Hepatol. 2026;32(1):339-352. PMID 41287437 — tags: [cohort] — cited by: masld-related-hepatocellular-carcinoma.md
  • Copil FD, Campani C, Lequoy M, et al. No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC. Liver Int. 2024;44(4):931-943. PMID 38291735 — tags: [primary-research] — cited by: masld-related-hepatocellular-carcinoma.md
  • Stefanini B, Piscaglia F, Marra F, et al. Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab. Liver Cancer. 2026;15(1):10-23. PMID 40567390 — tags: [primary-research] — cited by: masld-related-hepatocellular-carcinoma.md
  • Zeng RW, Yong JN, Tan DJH, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther. 2023;57(6):600-609. PMID 36625733 — tags: [meta-analysis] — cited by: masld-related-hepatocellular-carcinoma.md
  • Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(2):435-444.e6. PMID 35158055 — tags: [primary-research] — cited by: masld-related-hepatocellular-carcinoma.md

Cardiovascular, renal and extrahepatic outcomes

19 papers.

  • Bilson J et al. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1):101506. PMID 38141808 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Byrne CD et al. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. PMID 25920090 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Chen Q et al. Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Commun Med (Lond). 2025;5(1):492. PMID 41272273 — tags: [cardiovascular, mortality] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Duell PB et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. PMID 35418240 — tags: [cardiovascular, review] — cited by: cardiovascular-and-extrahepatic-outcomes.md, guidelines.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md
  • Ha NB et al. The bidirectional relationship between nonalcoholic fatty liver disease and sarcopenia. Hepatol Int. 2022;16(3):489-491. PMID 35347595 — tags: [editorial] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Kalligeros M et al. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism. 2024;160:156004. PMID 39182603 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Lee HH et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533-540. PMID 37907259 — tags: [cardiovascular] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Lim TS et al. Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank. J Cachexia Sarcopenia Muscle. 2025;16(2):e13757. PMID 40035094 — tags: [cardiovascular] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Mantovani A et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-913. PMID 34555346 — tags: [cardiovascular, meta-analysis] — cited by: cardiovascular-and-extrahepatic-outcomes.md, overview.md
  • Mantovani A et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-788. PMID 33685968 — tags: [meta-analysis] — cited by: cardiovascular-and-extrahepatic-outcomes.md, overview.md
  • Mantovani A et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156-162. PMID 33303564 — tags: [meta-analysis] — cited by: cardiovascular-and-extrahepatic-outcomes.md, overview.md
  • Marjot T et al. Skeletal muscle and MASLD: Mechanistic and clinical insights. Hepatol Commun. 2025;9(6). PMID 40408301 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Petermann-Rocha F et al. Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants. J Hepatol. 2022;76(5):1021-1029. PMID 35085594 — tags: [primary-research] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Simon TG et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867-1875. PMID 34489307 — tags: [cardiovascular, histology] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Targher G et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. PMID 27212244 — tags: [cardiovascular, meta-analysis] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Targher G et al. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578-588. PMID 33961787 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Targher G et al. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691-702. PMID 38228377 — tags: [cardiovascular, review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Zannad F et al. MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design. J Am Coll Cardiol. 2026;87(15):2006-2033. PMID 41636667 — tags: [review] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Zhou XD et al. Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD. Hepatology. 2026;84(2):529-541. PMID 41400631 — tags: [cardiovascular, fibrosis] — cited by: cardiovascular-and-extrahepatic-outcomes.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Capone F, Häseli SP, Liu L, et al. HFpEF and MASLD: converging mechanisms and clinical implications. Nat Rev Cardiol. 2026;23(8):584-608. PMID 41735546 — tags: [primary-research] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Driessen S, Francque SM, Anker SD, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82(2):487-503. PMID 38147315 — tags: [primary-research] — cited by: cardiovascular-and-extrahepatic-outcomes.md
  • Roca-Fernandez A, Banerjee R, Thomaides-Brears H, et al. Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study. J Hepatol. 2023;79(5):1085-1095. PMID 37348789 — tags: [primary-research] — cited by: cardiovascular-and-extrahepatic-outcomes.md

MASLD and type 2 diabetes

6 papers.

  • Cao L et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Med. 2024;22(1):101. PMID 38448943 — tags: [diabetes, meta-analysis, prevalence] — cited by: masld-and-type-2-diabetes.md
  • Cusi K et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. PMID 40434108 — tags: [diabetes, guideline] — cited by: guidelines.md, masld-and-type-2-diabetes.md, red-flags-and-safety-concerns.md
  • Golabi P et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 2023;146:155642. PMID 37380016 — tags: [diabetes, mortality] — cited by: masld-and-type-2-diabetes.md
  • Kim KS et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384:e076388. PMID 38350680 — tags: [cardiovascular, diabetes] — cited by: masld-and-type-2-diabetes.md
  • Qi X et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83(3):661-678. PMID 38722246 — tags: [diabetes, prevalence, review] — cited by: masld-and-type-2-diabetes.md
  • Younossi ZM et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e8. PMID 38521116 — tags: [diabetes, meta-analysis, prevalence] — cited by: masld-and-type-2-diabetes.md, overview.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Barb D, Kalavalapalli S, Godinez Leiva E, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol. 2025;82(6):979-991. PMID 39824443 — tags: [primary-research] — cited by: masld-and-type-2-diabetes.md
  • de Vries M, Westerink J, Kaasjager KHAH, et al. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(12):3842-53. PMID 32827432 — tags: [meta-analysis, systematic-review] — cited by: masld-and-type-2-diabetes.md
  • Zhou XD, Chen QF, Kim SU, et al. Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD. Clin Gastroenterol Hepatol. 2026;24(5):1332-1343. PMID 41076043 — tags: [primary-research] — cited by: masld-and-type-2-diabetes.md

Lean MASLD

6 papers.

  • Cheah MCC et al. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis. Hepatol Int. 2025;19(3):607-618. PMID 40087205 — tags: [lean, meta-analysis, prevalence] — cited by: lean-masld.md
  • Chen F et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology. 2020;71(4):1213-1227. PMID 31442319 — tags: [lean] — cited by: lean-masld.md
  • Danpanichkul P et al. Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations. Clin Mol Hepatol. 2025;31(1):74-89. PMID 39439408 — tags: [lean, review] — cited by: lean-masld.md
  • Long MT et al. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022;163(3):764-774.e1. PMID 35842345 — tags: [guideline, lean] — cited by: guidelines.md, lean-masld.md, red-flags-and-safety-concerns.md
  • Sato-Espinoza K et al. Clinical and Genetic Predictors of Non-Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals. Liver Int. 2025;45(10):e70300. PMID 40944478 — tags: [fibrosis, genetics, lean] — cited by: lean-masld.md
  • Wakabayashi SI et al. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59(6):494-503. PMID 38570344 — tags: [lean] — cited by: lean-masld.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Al Ta'ani O, Alhalalmeh Y, Alabdallat M, et al. Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis. Clin Transl Gastroenterol. 2026;17(4):e00974. PMID 41614694 — tags: [primary-research] — cited by: lean-masld.md
  • Ghani L, Aboona MB, Faulkner CS, et al. Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study. J Gastroenterol Hepatol. 2025;40(8):1919-1925. PMID 40406910 — tags: [primary-research] — cited by: lean-masld.md
  • Huo Z, Chen Y, Huang Y, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. 2026;75(4):772-785. PMID 41093635 — tags: [cohort] — cited by: lean-masld.md
  • Nso N, Mergen D, Ikram M, et al. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis. Curr Probl Cardiol. 2024;49(6):102569. PMID 38599554 — tags: [meta-analysis] — cited by: lean-masld.md
  • Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024;18(5):1396-1415. PMID 39117942 — tags: [meta-analysis, systematic-review] — cited by: lean-masld.md
  • Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis. Ann Hepatol. 2024;29(3):101288. PMID 38278181 — tags: [meta-analysis] — cited by: lean-masld.md

Guidelines, consensus statements and public health

14 papers.

  • Akuta N et al. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. J Gastroenterol. 2026;61(6):693-710. PMID 42120590 — tags: [guideline] — cited by: guidelines.md
  • Chalasani N et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. PMID 28714183 — tags: [guideline] — cited by: guidelines.md
  • Cusi K et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. PMID 35569886 — tags: [guideline] — cited by: guidelines.md
  • Diaz LA et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann Hepatol. 2025;30(2):101903. PMID 40089151 — tags: [guideline] — cited by: guidelines.md, red-flags-and-safety-concerns.md
  • European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67(11):2375-2392. PMID 38869512 — tags: [guideline] — cited by: guidelines.md
  • European Association for the Study of the Liver (EASL) et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121-40. PMID 27053230 — tags: [primary-research] — cited by: guidelines.md
  • European Association for the Study of the Liver (EASL) et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. PMID 27062661 — tags: [guideline] — cited by: guidelines.md
  • European Association for the Study of the Liver (EASL) et al. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17(4):374-444. PMID 38852583 — tags: [guideline] — cited by: guidelines.md
  • Ginès P et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75(1):219-228. PMID 34537988 — tags: [fibrosis, review] — cited by: guidelines.md
  • Lazarus JV et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. PMID 34707258 — tags: [guideline] — cited by: guidelines.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md
  • Romero-Gómez M et al. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis. Gastroenterol Hepatol. 2025;48(8):502442. PMID 40221023 — tags: [guideline] — cited by: guidelines.md
  • Vos MB et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319-334. PMID 28107283 — tags: [guideline] — cited by: guidelines.md
  • Younossi ZM et al. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026;24(9):2333-2347. PMID 41950980 — tags: [guideline] — cited by: clinical-trials-landscape.md, guidelines.md, red-flags-and-safety-concerns.md
  • Zhang L et al. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med. 2024;5(7):797-815.e2. PMID 38677287 — tags: [guideline] — cited by: guidelines.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Associazione Italiana per lo Studio del Fegato (AISF). AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. Dig Liver Dis. 2026;58(5):599-607. PMID 41864758 — tags: [guideline] — cited by: guidelines.md
  • Duseja A, Singh SP, De A, et al. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol. 2023;13(2):273-302. PMID 36950481 — tags: [guideline] — cited by: guidelines.md
  • Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354:i4428. PMID 27605111 — tags: [primary-research] — cited by: guidelines.md
  • Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. PMID 40467095 — tags: [randomised-trial] — cited by: guidelines.md, other-pharmacotherapy.md
  • Sohn W, Lee YS, Kim SS, et al. KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol. 2025;31(Suppl):S1-S31. PMID 39967303 — tags: [guideline] — cited by: guidelines.md

Clinical trials landscape and drug pipeline

1 papers.

  • Noureddin M. MASH clinical trials and drugs pipeline: An impending tsunami. Hepatology. 2025;82(5):1325-1340. PMID 38502810 — tags: [review] — cited by: clinical-trials-landscape.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. PMID 39412509 (NCT04822181) — tags: [primary-research] — cited by: clinical-trials-landscape.md
  • Rasmussen DGK, Anstee QM, Torstenson R, et al. NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned. J Hepatol. 2023;78(4):852-865. PMID 36526000 — tags: [biomarker, review] — cited by: clinical-trials-landscape.md
  • Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714-725. PMID 36958367 — tags: [primary-research] — cited by: clinical-trials-landscape.md

Safety, drug hepatotoxicity and alcohol

7 papers.

  • Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41(4):690-5. PMID 15789367 — tags: [review, statins] — cited by: red-flags-and-safety-concerns.md
  • Fromenty B. Drug-induced liver injury in obesity. J Hepatol. 2013;58(4):824-6. PMID 23298629 — tags: [review] — cited by: red-flags-and-safety-concerns.md
  • Gawrieh S et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol. 2024;81(4):600-608. PMID 38762169 — tags: [primary-research] — cited by: red-flags-and-safety-concerns.md
  • Mallet M et al. Editorial: statin use in patients with NAFLD-safety concerns, decreased awareness or both?. Aliment Pharmacol Ther. 2021;54(11-12):1499-1500. PMID 34741325 — tags: [editorial, statins] — cited by: red-flags-and-safety-concerns.md
  • Pastori D et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441-451. PMID 34133035 — tags: [meta-analysis, statins] — cited by: red-flags-and-safety-concerns.md
  • Sookoian S et al. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?. Gastroenterology. 2016;150(8):1698-1703.e2. PMID 26775630 — tags: [alcohol, review] — cited by: red-flags-and-safety-concerns.md
  • Åberg F et al. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol. 2023;78(1):191-206. PMID 36063967 — tags: [alcohol, prevalence, review] — cited by: red-flags-and-safety-concerns.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200-206. PMID 36252717 — tags: [primary-research] — cited by: red-flags-and-safety-concerns.md
  • Jung YM, Kim T, Oh MJ, et al. Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study. Hepatol Int. 2026;20(1):69-80. PMID 41307877 — tags: [cohort] — cited by: red-flags-and-safety-concerns.md
  • Marxer CA, Ebrahimi F, Bergman D, et al. Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study. EClinicalMedicine. 2025;83:103238. PMID 40630617 — tags: [cohort] — cited by: red-flags-and-safety-concerns.md
  • Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. PMID 27677775 — tags: [review, safety] — cited by: red-flags-and-safety-concerns.md

Patient experience, stigma and quality of life

12 papers.

  • Alem SA et al. Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol. 2021;74(5):1261-1262. PMID 33497764 — tags: [editorial] — cited by: patient-experience-and-advocacy.md
  • Avery L et al. Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. Clin Gastroenterol Hepatol. 2017;15(12):1968-1971. PMID 28624648 — tags: [primary-research] — cited by: patient-experience-and-advocacy.md
  • Berg J et al. Understanding MASLD and diabetes through lived experience. Diabetologia. 2026. PMID 42525136 — tags: [diabetes, editorial] — cited by: patient-experience-and-advocacy.md
  • Doward LC et al. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. Patient. 2021;14(5):533-543. PMID 33336323 — tags: [quality-of-life, review] — cited by: patient-experience-and-advocacy.md
  • Fouad Y et al. Evaluation of Stigma Toward Fatty Liver Disease. Endocr Metab Immune Disord Drug Targets. 2025. PMID 40337974 — tags: [stigma] — cited by: patient-experience-and-advocacy.md
  • Ley SL et al. Insight Into the Adolescent Patient Experience With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2022;75(1):88-96. PMID 35442241 — tags: [primary-research] — cited by: patient-experience-and-advocacy.md
  • Sena E et al. Patient-reported outcomes in NAFLD/NASH clinical trials: A blind spot that needs addressing. JHEP Rep. 2023;5(1):100597. PMID 36536958 — tags: [quality-of-life] — cited by: patient-experience-and-advocacy.md
  • Stine JG et al. The health care experience of adults with metabolic dysfunction-associated steatohepatitis and influence of PNPLA3: A qualitative study. Hepatol Commun. 2024;8(6). PMID 38780312 — tags: [pnpla3] — cited by: patient-experience-and-advocacy.md
  • Younossi ZM. Chronic liver disease and health-related quality of life. Gastroenterology. 2001;120(1):305-7. PMID 11208742 — tags: [editorial, quality-of-life, review] — cited by: patient-experience-and-advocacy.md
  • Younossi ZM et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80(3):419-430. PMID 37984709 — tags: [stigma] — cited by: patient-experience-and-advocacy.md
  • Younossi ZM et al. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology. 2025;81(4):1318-1327. PMID 39250515 — tags: [fibrosis, quality-of-life, resmetirom, trial] — cited by: patient-experience-and-advocacy.md
  • Younossi ZM et al. Measuring health-related quality of life and patient-reported outcomes in chronic liver disease. J Hepatol. 2026;84(2):457-472. PMID 41072803 — tags: [quality-of-life, review] — cited by: patient-experience-and-advocacy.md

Added in the 2026-09-02 depth pass (all retrieved from live PubMed E-utilities queries in that session):

  • Li S, Li S, Duan F, et al. Depression and NAFLD risk: A meta-analysis and Mendelian randomization study. J Affect Disord. 2024;352:379-385. PMID 38387674 — tags: [meta-analysis, mendelian-randomisation] — cited by: patient-experience-and-advocacy.md
  • Mikkelsen ACD, Kjærgaard K, Schapira AHV, et al. The liver-brain axis in metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2025;10(3):248-258. PMID 39701123 — tags: [review] — cited by: patient-experience-and-advocacy.md
  • Stepanova M, Henry L, Younossi ZM. Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2023;27(2):483-513. PMID 37024220 — tags: [review] — cited by: patient-experience-and-advocacy.md

Independent-audit additions, 2026-09-02

15 papers found while re-running asserted absences and checking claim direction.

  • Alkhouri N et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77(3):607-618. PMID 35439567 — tags: [combination, trial] — cited by: clinical-trials-landscape.md
  • Yu Y et al. Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study. Front Endocrinol. 2023;14:1156381. PMID 37223039 — tags: [diabetes, genetics] — cited by: masld-and-type-2-diabetes.md
  • Ni X et al. Association between nonalcoholic fatty liver disease and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. Diabetes Res Clin Pract. 2023;206:110993. PMID 37931882 — tags: [diabetes, genetics] — cited by: masld-and-type-2-diabetes.md
  • Liu Z et al. Dissecting the shared genetic architecture between nonalcoholic fatty liver disease and type 2 diabetes. Hum Mol Genet. 2025;34(4):338-346. PMID 39690818 — tags: [diabetes, genetics] — cited by: masld-and-type-2-diabetes.md
  • Vaz J et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025;83(5):1011-1022. PMID 40228582 — tags: [alcohol, classification] — cited by: lean-masld.md
  • Tavaglione F et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025;83(5):1023-1034. PMID 40517819 — tags: [alcohol, classification] — cited by: lean-masld.md
  • Lim WH et al. Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of MASH Cirrhosis Among Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2026;24(8):2181-2190. PMID 41284513 — tags: [cirrhosis, transplant] — cited by: cirrhosis-and-decompensation.md
  • Kaushal K et al. From Policy to Practice: Knowledge gaps and training outcomes related to MASLD guidelines among medical officers in Chhattisgarh, India. BMC Health Serv Res. 2026;26(1):579. PMID 41845319 — tags: [guideline, implementation] — cited by: guidelines.md
  • Pustjens J et al. Underuse of statins in MASLD despite population-based associations with lower liver stiffness. JHEP Rep. 2026;8(4):101764. PMID 41861677 — tags: [statin, cardiovascular] — cited by: red-flags-and-safety-concerns.md
  • Liu C et al. Sleeve gastrectomy versus Roux-en-Y gastric bypass for nonalcoholic fatty liver disease: a systematic review and meta-analysis. Surg Obes Relat Dis. 2026. PMID 42420150 — tags: [bariatric, meta-analysis] — cited by: bariatric-and-metabolic-surgery.md
  • Premkumar M et al. Recompensation of decompensated cirrhosis in a spectrum of metabolic dysfunction-related steatotic liver disease. Hepatology. 2026. PMID 42467948 — tags: [cirrhosis, recompensation] — cited by: cirrhosis-and-decompensation.md
  • Yang Y et al. A qualitative study on the self-management experience and needs of postmenopausal patients with MASLD. Front Public Health. 2026;14:1828862. PMID 42529177 — tags: [patient-experience, qualitative] — cited by: patient-experience-and-advocacy.md
  • Allen AM et al. Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds. Hepatol Commun. 2026;10(9):e1012. PMID 42566274 — tags: [non-invasive-test, screening] — cited by: noninvasive-assessment.md, red-flags-and-safety-concerns.md
  • Miyake T et al. Efficacy of Luseogliflozin Added to Semaglutide in Patients With MASH and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial. Diabetes Obes Metab. 2026. PMID 42605535 — tags: [diabetes, trial] — cited by: masld-and-type-2-diabetes.md
  • Shea Wynyard S et al. Lived Experience, Concerns, and Support Needs of Adults with MASLD: A Qualitative Study. Healthcare (Basel). 2026;14(16):2569. PMID 42651339 — tags: [patient-experience, qualitative] — cited by: patient-experience-and-advocacy.md
  • Godwin KM et al. A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol. BMC Health Serv Res. 2025;25(1):645. PMID 40325466 — tags: [care-pathway, trial-protocol] — cited by: clinical-trials-landscape.md

Coverage note

This bibliography is generated from the wiki pages themselves, so it is complete by construction with respect to what the pages cite. It is not a complete bibliography of MASLD: the union query (MASLD OR NAFLD OR MASH OR NASH OR "steatotic liver disease") returned 78,992 PubMed records on 2026-09-02. Selection favours meta-analyses, large cohorts, registration trials, guidance documents and mechanistic papers with human data.

A further 15 unique records are catalogued only in the supporting literature files, including the 2026 EASL holistic guidance (PMID 42617506). Their citations were verified against live PubMed on the same date. The 22 wiki pages cite 360 distinct PubMed records, and the condition's wiki-plus-literature union holds 375 verified PubMed records in total.